Prostate Health · BPH Treatment · Evidence

Aquablation Clinical Study Results Compared to TURP

The published trials behind Aquablation — WATER, WATER II and the pooled studies — year by year, with the limits stated. For how the procedure works and who it suits, see Aquablation therapy.

The question most men ask

Is there a best surgery for an enlarged prostate?

No single one. The AUA guideline names many surgical options for BPH and ties each to prostate size, anatomy, bleeding risk and what the man wants to preserve; the right one is the one that fits those four things. This page shows what one of them, Aquablation, did in its trials, so you can weigh it.

For every option side by side, see BPH treatment options, or go straight to Rezum, UroLift, GreenLight laser or prostate artery embolization.

The trial data

Five years, measured

The International Prostate Symptom Score, 0 to 35, is what the trials followed. Every point on this chart comes from a published paper, named beside it; what we could not verify is not drawn.

Symptom score over 60 months · trial data

Line chart of symptom score over sixty months for Aquablation and TURP cohorts, with severity bands and two dashed reference levels; values are listed in the readout and the table below the chart SevereModerateMild05101520253035061224364860IPSS score (0–35, lower is better)Months after the procedureDrug therapy, about 5 points †Non-resective procedures, about 10 points †
  • PMID 39539565 — Berjaoui MB et al. WATER vs WATER II 5-year update. BJUI Compass 2024;5:1023–33.
  • PMID 30734990 — Desai M et al. WATER II six-month results. BJU Int 2019;124:321–8.
  • PMID 32333733 — Desai M et al. WATER II two-year results. Can J Urol 2020;27:10147–53.
  • PMID 37115632 — Bhojani N et al. WATER II final five-year results. J Urol 2023;210:143–53.
  • PMID 41148264 — Siqueira MHB et al. Pooled analysis of WATER, WATER II, OPEN WATER, FRANCAIS WATER and JAPAN PMS. World J Urol 2025;43:635.
  • PMID 33392647 — Whiting D et al. Single-centre OPEN WATER experience, athermal haemostasis, 1-year. World J Urol 2021;39:3019–24.
  • † Reference levels: PROCEPT BioRobotics.
Severity bands follow the usual IPSS reading: 0–7 mild, 8–19 moderate, 20–35 severe. “Score” plots values the papers state as absolute scores; “Points improved” plots the change-from-baseline figures the papers state. The two views are not mixed, and no value is read off a manufacturer graphic — which is why the randomized WATER cohort shows only its baseline and five-year scores here, with its yearly figures in the other view. The dashed reference levels (†) come from PROCEPT BioRobotics: drug therapy generally improves the IPSS by about 5 points, non-resective procedures by about 10; in the Score view they are drawn 5 and 10 points below the WATER baseline of 22.9. Individual results vary; these are trial averages.

The same numbers, as a table

Every IPSS value plotted in the chart above, with its month, measure and PubMed ID.
Study and groupMonthMeasureIPSSPMID
WATER · Aquablation (30–80 mL, randomized)0Score22.939539565
WATER · Aquablation6Points improved16.935150215
WATER · Aquablation12Points improved15.130552937
WATER · Aquablation24Points improved14.731028614
WATER · Aquablation36Points improved14.432065861
WATER · Aquablation60Points improved15.135150215
WATER · Aquablation60Score7.039539565
WATER · TURP (control arm)6Points improved15.135150215
WATER · TURP12Points improved15.130552937
WATER · TURP24Points improved14.931028614
WATER · TURP36Points improved13.932065861
WATER · TURP60Points improved13.235150215
WATER II (80–150 mL, single-arm)0Score23.230734990
WATER II3Score6.730734990
WATER II24Score5.832333733
WATER II24Points improved17.032333733
WATER II60Score6.8 (baseline 22.6 in this analysis)37115632
WATER II60Points improved15.937115632
Five studies pooled (n=528, 20–242 mL)0Score21.541148264
Five studies pooled6Score5.841148264
Five studies pooled12Score6.641148264
OPEN WATER, one UK centre (n=55)0Score21.733392647
OPEN WATER, one UK centre12Score6.133392647

Reference levels on the chart (†): PROCEPT BioRobotics — drug therapy about 5 IPSS points of improvement, non-resective procedures about 10. Not plotted: any value we could not find stated in a paper’s abstract.

Water Study

WATER (30–80 mL): Aquablation vs TURP, randomized and double-blind

The first WATER Study (Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue) compared the safety and effectiveness of Aquablation therapy to the gold standard surgical treatment for enlarged prostate, transurethral resection of the prostate (TURP). A double-blind prospective, randomized trial compared both treatments for prostates measuring in the 30 to 80 milliliter (mL) range in size. The results were the following:

  • Superior safety endpoints for Aquablation compared to TURP at 3 months (incontinence, erectile dysfunction, ejaculatory dysfunction, blood transfusion)
  • Comparable improvements in urinary symptoms measured by International Prostate Symptom Score (IPSS) for Aquablation versus TURP

What the trials actually showed. In the WATER trial — a double-blind randomized comparison of Aquablation against TURP in prostates of 30 to 80 cc — symptom relief at six months was non-inferior to TURP: as good, rather than better. Where Aquablation did prove superior was safety, on the trial’s primary safety endpoint, and among sexually active men the rate of anejaculation was markedly lower. Those are two different claims and we keep them apart.

181 men were randomized two to one, Aquablation to TURP. The operation took about 33 minutes against 36, and the resection itself about 4 minutes against 27 (Gilling et al., J Urol 2018, PubMed). The two groups’ symptom improvements stayed close year by year: 15.1 and 15.1 points at one year, 14.7 and 14.9 at two, 14.4 and 13.9 at three.

Comparable Symptom Score (IPSS) Improvement Compared to TURP at 6 Months

At six months the symptom score had improved by 16.9 points after Aquablation and 15.1 after TURP — the trial’s non-inferiority result. At five years the figures were 15.1 and 13.2 points, not a significant difference (p = 0.2764); flow rate had improved by 125% against 89%, and men treated with Aquablation had a 51% lower risk of needing another BPH treatment (Gilling et al., Can J Urol 2022).

Greater IPSS Improvement for Aquablation vs TURP in 50 to 80 mL Prostates

In men whose prostates were 50 mL or larger, symptom scores at five years had improved 3.5 points more after Aquablation than after TURP. That is a subgroup finding, not the trial’s primary result.

Superior Side Effect Profile and Sexual Side Effect Results for Aquablation vs TURP

On the trial’s primary safety measure, events at three months were recorded in 26% of men after Aquablation and 42% after TURP (superiority, p = 0.0149). Among sexually active men, loss of ejaculation was 10% against 36% (p = 0.0003), and at five years procedure-related ejaculatory dysfunction was 7% against 25%.

Water II Study

WATER II (80–150 mL): large glands, single-arm

The WATER II Study looked at men with larger and more difficult to treat prostates in the range of 80 to 150 mL in size.

Because WATER II had no comparison group, it shows how Aquablation performed in large glands, not how it compares with TURP there.

101 men took part, with an average prostate of 107 mL. The trial’s three-month safety goal was met: 45.5% had an event on its safety scale, against a target below 65%. Symptom scores fell from 23.2 to 6.7 by three months, and flow rate rose from 8.7 to 18.8 mL/s; men stayed in hospital 1.6 days on average (same day to six days); bleeding needing intervention or transfusion was recorded in 8 men before discharge and 6 after (Desai et al., BJU Int 2019).

At two years the score was 5.8, and all but 2 of 74 men had stopped their alpha-blockers and all but 4 of 32 their 5-alpha-reductase inhibitors (Desai et al., Can J Urol 2020). At five years the score was 6.8, flow rate had risen from 8.6 to 17.1 mL/s, 96.3% of men had not needed a second BPH procedure, and results did not differ between glands above and below 100 mL (Bhojani et al., J Urol 2023).

Beyond the two trials

Pooled and real-world results

A 2025 analysis pooled five prospective studies — WATER, WATER II, OPEN WATER, FRANCAIS WATER and a Japanese post-market study — covering 528 men with prostates from 20 to 242 mL (average 71.7). Symptom scores fell from 21.5 to 5.8 at six months and were 6.6 at a year; flow rate rose from 8.1 to 20.5 mL/s (Siqueira et al., World J Urol 2025).

One UK centre that controlled bleeding without heat reported 55 men whose scores fell from 21.7 to 6.1 at a year, with no significant change in erectile or ejaculatory function scores (Whiting et al., World J Urol 2021).

These are prospective studies, mostly supported by the manufacturer, and apart from WATER none is randomized.

The limits

Reading the numbers honestly

A non-inferiority trial asks whether a new treatment is not meaningfully worse than the standard; WATER answered yes for symptom relief. A superiority result says it is better; WATER showed that only for its safety measure.

The AUA guideline calls Aquablation’s sexual-function advantage theoretical: heat is not used to remove tissue, the reason may be the reduced removal near the verumontanum, and cautery used afterward to control bleeding may give some of it back.

The 50–80 mL advantage is a subgroup finding. Subgroups are where trials generate questions, not where they settle them.

PROCEPT BioRobotics recognizes the importance of strong clinical data to support the use of Aquablation therapy with the AquaBeam system for the treatment of benign prostatic hyperplasia (BPH). These studies were largely supported by the company, and the papers disclose their authors’ financial relationships with it; we say so because it is part of reading them.

These are published trial results, not this practice’s own figures. Individual results vary.

Common questions

Frequently Asked Questions

What is the IPSS?

The International Prostate Symptom Score: seven questions about urinary symptoms, each scored 0 to 5, for a total of 0 to 35. A score of 0–7 is usually read as mild, 8–19 as moderate and 20–35 as severe. Lower is better.

What does “non-inferior” mean?

That the trial was designed to show Aquablation was not meaningfully worse than TURP on symptom relief — and it showed that. It is not the same as showing it was better. WATER did show Aquablation was superior on its primary safety measure, which is a different question.

Why is TURP only in the “points improved” view of the chart?

Because the abstracts we verified report TURP’s results as change from baseline, not as absolute scores. We plot only values a paper states; we do not derive numbers or trace them off a manufacturer’s chart.

Are these your own results?

No. They are published trial results. We do not publish our own figures without a denominator — the number of men treated — to measure them against.

To request your consultation, please call (305) 672-4222 or contact us online today!

Contact Us

We’re here to help. Schedule your visit or ask a question today.

No question is too small — and nothing you share here surprises us. Reach out however feels easiest.

  • Call(305) 672-4222
  • Visit12411 Biscayne Boulevard
    North Miami, FL 33181
  • HoursMonday–Friday, 9:00 am – 5:00 pm

Your message goes to Dr. Robbins’ own team — you’ll hear back within one business day.

Get More Information

By sending this form you agree to our Terms of Service, Privacy Policy, and Notice of Privacy Practices.

Your message is confidential. We’ll respond within one business day.

We’re Here When You Need Us

Our Office

Visit us in North Miami, or call to book your appointment.

North Miami

  • Address12411 Biscayne Boulevard
    North Miami, FL 33181
  • Phone(305) 672-4222
  • Fax(305) 944-3624
Office hours
Monday – Friday9:00 am – 5:00 pm
Saturday – SundayClosed

Associations

Proud Members Of

American Board of Urology American College of Surgeons NYU Medical Center Miller School of Medicine Brandeis University Greenlight